New peer-reviewed publication on CM-Glucan Nu
Exciting news: a new article on CM-Glucan Nu has recently been published in the journal EC Nutrition. The paper describes the effects of our active ingredient CM-Glucan Nu on respiratory health and quality of life in self-described pollen-allergy sufferers.
Beta-Glucan, derived from baker’s yeast and one of the most common immune-boosters in supplement industry, is a polysaccharide that is naturally water-insoluble and poorly absorbable. However, through a process called carboxymethylation, beta-Glucan is converted into a highly soluble form, called carboxymethyl-glucan (CM-Glucan). This transformation makes CM-Glucan Nu suitable for a wide range of supplement applications.
The randomized, placebo-controlled, double-blind clinical study investigated the effects of daily intake of 100 mg CM-Glucan Nu on physical and psychological health traits, offering new insights into potential benefits for allergy-sufferers.
The study’s key findings demonstrate that CM-Glucan Nu:
- Significantly reduces inflammatory cytokines in the saliva.
- Improves subjective allergy-symptoms (like fatigue, reduced productivity, tiredness, poor concentration, headache) and intensity of symptoms.
- Reduces negative psychological mood states.
Furthermore, the study confirms the efficacy of a daily intake of 100 mg CM-Glucan – to our actual knowledge the lowest dose of a yeast-derived beta-Glucan to show positive effects in a placebo-controlled clinical trial.
These results show that CM-Glucan Nu can benefit allergy-sufferers by significantly alleviating allergy symptoms and improving emotional well-being.
Read the full article here: ECronicon - Effect of CM-Glucan Supplementation on Respiratory Health and Quality of Life in Self-Described Pollen-Allergy Sufferers
